Download PDF
CC BY-NC-ND 4.0 · Journal of Health and Allied Sciences NU 2012; 02(02): 36-40
DOI: 10.1055/s-0040-1703568
Original Article

INFLUENCE OF BIOENHANCERS ON THE RELEASE PATTERN OF NIOSOMES CONTAINING METHOTREXATE

Narayana Charyulu R.
1   Department of Pharmaceutics, N.G.S.M. Institute of Pharmaceutical Sciences, Paneer, Deralakatte, Mangalore - 575 018
,
Gandhi Kinjal B.
1   Department of Pharmaceutics, N.G.S.M. Institute of Pharmaceutical Sciences, Paneer, Deralakatte, Mangalore - 575 018
,
Jobin Jose
1   Department of Pharmaceutics, N.G.S.M. Institute of Pharmaceutical Sciences, Paneer, Deralakatte, Mangalore - 575 018
,
Sneh Priya
1   Department of Pharmaceutics, N.G.S.M. Institute of Pharmaceutical Sciences, Paneer, Deralakatte, Mangalore - 575 018
,
Shastry C. S.
1   Department of Pharmaceutics, N.G.S.M. Institute of Pharmaceutical Sciences, Paneer, Deralakatte, Mangalore - 575 018
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints

Abstract

The aim of present study was to prepare sustained release formulations of niosomes of methotrexate (MTX) alone (N1 to N10) and along withbioenhancers (NB1 to NB9) by thin film hydration technique using span 60 as surfactant,cholesterol as membrane stabilizing agent, curcumin and piperine as bioenhancers and dicetyl phosphate (DCP) as charge inducing agent. All the formulations of niosomeswere characterized on the basis of physical appearance and entrapment efficiency. The invitro releasestudies of optimized formulation of niosomes of MTX alone and along with bioenhancers were performed and compared with pure drug released. The entrapment efficiency of MTX in optimized formulation of niosomes containing MTX along with bioenhancers was found to 56.9% and entrapment efficiency of bioenhancerscurcumin and piperinewas found to be 40.30% and 69.1%respectively. In vitro drug release of optimized formulationsof niosomes of MTX without and with bioenhancers (F3) was found to be 98.89% and 60.97% at the end of 12 h respectively. Results concluded that Niosomes of MTX containing bioenhancers followed sustain release pattern.

Keywords

Methotrexate - Thin Film Hydration Technique - Entrapment efficiency - Invitro study


Publication History

Article published online:
02 March 2020

© .

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Aggarwal B B, Kumar A, Bharti A C. Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Res. 2003; 23(1A):363–98.
  • 2 Harsh Mohan. “Neoplasia” in textbook of pathology, 2005; P:142, Jaypee Brothers, New Delhi.
  • 3 Harvey Ladies et al. “Cancer” Molecular cell biology, 2005; P:1267, Scientific American book, London.
  • 4 M. Reza Mozafari. Nanocarrier Technologies: Frontiers of Nanotherapy. 2006; P: 1-16, Springer, Netherlands.
  • 5 Torchillin VP. Multifunctional nanocarriers. Adv drug del rev. 2006; 58(14):1533–9.
  • 6 Torchillin V P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. The AAPS Journal. 2007; 9(2):E128–47.
  • 7 Gottesman M.M. Mechanisms of cancer drug resistance. Annual rev. med. 2002; (53):615-27.
  • 8 Zhang S, X, Morris M E. Flavanoids are inhibitors of breast cancer resistance protein (ABCG2)- Mediated transport. Mole pharmaco. 2004; 65(5):1208-16.
  • 9 Joshi M, Misra A. Dry powder inhalation of liposomal ketotifen fumarate: Formulation and characterization. Int. J. Pharm. 2001; 223(1-2):15–27.
  • 10 Singh C H, Jain C P, Kumar B N. Formulation, characterization, stability and in vitro evaluation of nimesulide niosomes. Pharmacophore. 2011; 2(3):168-85.
  • 11 Karki R, Mamatha G C, Subramanya G, Udupa N. Preparation, characterization and tissue disposition of niosomes containing isoniazid. Rasayan J. Chem. 2008; 1(2):224-7.
  • 12 Yang Z J, Huang W H, Wong Y.F, Zhao Z Z, Liu L. Development of liposomal salbutamol sulphate dry powder inhaler formulation. Biol. Pharm. Bull. 2010; 33(3):512-7.